Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC (INTREPID2566)

Neuren Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Brain Injuries

Treatments: Drug: Placebo; Drug: NNZ-2566

Study type: Interventional

Funder types: Industry

Identifiers

NCT01366820

Neu-2566-TBI-002

Details and patient eligibility

About

The purpose of this study is to determine whether NNZ-2566 is safe and effective in the treatment of Traumatic Brain Injury (TBI).

Full description

Moderate to severe traumatic brain injury frequently results in persistent problems with memory, attention span, mood and more complex brain functioning such as planning and organizing. There are currently no drugs available to reduce the brain damage or the persisting symptoms that result from TBI. The longer term goal of this study is to provide physicians with a safe and effective treatment for TBI

Enrollment: 261 patients

Sex: All

Ages: 16 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Non-penetrating TBI.
• Age 16-75 years.
• Admission to hospital.
• Post resuscitation GCS 4-12.
• Have at least one reactive pupil.
• Able to receive investigational product within 8 hours of injury.
• Hemodynamically stable after resuscitation (systolic blood pressure (SBP) >100 mm Hg).
• Able to read and write English and have sufficient motor dexterity prior to injury to undertake the neuropsychological and activities of daily living (ADL) testing, in the opinion of the investigator, at 1 month (defined as 4-6 weeks) and 3 months (defined as 12-14 weeks) post injury.

Exclusion criteria

• Penetrating brain injury.

• Spinal cord injury.

• Presence or known history of prior cerebral injury requiring hospitalization that would, in the opinion of the Investigator, interfere with or bias the assessment of efficacy.

• Non-traumatic brain injury.

• Known history of any medical or psychiatric disorder, or any severe concomitant disease that would, in the opinion of the Investigator, interfere with or bias the assessment of efficacy.

• Significant non-central nervous system (CNS) injuries sustained at the time of the TBI would, in the opinion of the Investigator, interfere with or bias the assessment of efficacy.

• Weight >150 kg.

• Participation in another clinical trial within the previous 4 weeks.

• Clinical state requiring greater than 6 L blood, colloid or crystalloid fluid resuscitation prior to randomization.

• Pregnant or nursing mothers. Women of child-bearing potential must have a negative urine or blood test prior to randomization.

• Prior enrollment in this study.

• QTc Exclusions. The study will use the exclusion criteria as defined in ICH Guideline E14 to exclude patients with a risk of QT/QTc prolongation, as follows:

  • A marked baseline prolongation of corrected QT/QTc interval >450 ms.
  • History of risk factors for torsade de pointes (e.g. heart failure, hypokalemia (serum potassium at screening <3.0 mmol/L)or family history of long QT syndrome).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

261 participants in 2 patient groups, including a placebo group

NNZ-2566

Experimental group

Description:

20 mg/kg intravenous bolus infusion of NNZ-2566 over 10 minutes followed by a continuous intravenous infusion of 6 mg/kg/h (n=133) intravenous infusion of NNZ-2566 for a total of 72 consecutive hours.

Treatment:

Drug: NNZ-2566

Sodium Chloride (0.9%) for Injection

Placebo Comparator group

Description:

Intravenous bolus infusion of Sodium Chloride (0.9%) for Injection over 10 minutes followed by a continuous intravenous infusion of Sodium Chloride (0.9%) for Injection for a total of 72 consecutive hours.

Treatment:

Drug: Placebo